期刊文献+

骨转移生化代谢指标研究进展 被引量:3

Research progress of bone metabolic markers
原文传递
导出
摘要 骨代谢生化指标是骨吸收或骨生成过程中释放到血液中一些终末产物,通过酶联免疫吸附试验法(ELISA)检测,对骨转移的诊断和疗效评估具有较高的特异性和敏感性,相对于影像学检查更适合骨转移癌的早期诊断和疗效监测,在评估预后方面也具有一定的优越性。应用骨代谢生化指标联合影像学检查,对骨转移的早期诊断、监测疗效及评估预后在临床中的价值更大。 Biochemical markers of bone metabolism are some of the final product which are released into the blood during the process of bone resorption or bone formation. Accumulative evidence shows that biochemical markers of bone metabolism through enzyme-linked immunoassay (ELISA) are more sensitive and specific than imaging examination. Moreover, biochemical markers of bone metabolism also display their superiorities on the early diagonosis, monitoring efficacy and prognosis evaluation in patients with bone metastases. Applications of biochemical markers of bone metabolism combined with imaging examination are more value for the early diagonosis, monitoring efficacy and prognosis evaluation in patients with bone metastases.
出处 《国际肿瘤学杂志》 CAS 2013年第7期546-548,共3页 Journal of International Oncology
基金 大连市自然科学基金(2012-86)
关键词 肿瘤转移 骨代谢生化指标 Neoplasm metastases Biochemical markers of bone metabolism
  • 相关文献

参考文献2

二级参考文献28

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1571
  • 2Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bisphos- phonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer, 2003, 10:21-27.
  • 3Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with parnidronate. Eur J Cancer, 1998, 34: 2021-2026.
  • 4Costa L, Demers LM, Gouveia-Ohveira A, et al. Prospective evaluation of the peptide-botmd collagen type Ⅰ cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol, 2002, 20:850-856.
  • 5Lipton A, Cook RJ, Major P, et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist, 2007, 12:1035-1043.
  • 6Ali SM, Demers LM, Leitzel K, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol, 2004, 15:455-459.
  • 7Manders K, van de Poll-Franse LV, Creemers G J, et al. Clinical management of women with metastatic breast cancer : a descriptive study according to age group. BMC Cancer, 2006, 6:179.
  • 8Weinfurt KP, Castel LD, Li Y, et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care, 2004, 42 : 164-175.
  • 9Shimozuma K, Sonoo H, Fukunaga M, et al. Biochemical markers of bone turnover in breast cancer patients with bone metastases : a preliminary report. Jpn J Clin Oncol, 1999, 29:16-26.
  • 10Voorzanger-Rousselot N, Juillet F, Mareau E, et al. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer, 2006, 95 : 506-514.

共引文献16

同被引文献23

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部